Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical study in Australia to evaluate the safety, tolerability, and pharmacokinetics of its in-house developed antibiotic, MRX-5. The study will also explore the effects of food on the drug’s pharmacokinetics and is expected to conclude in 2024.
Innovative Antibiotic Targeting Mycobacterium Infections
MRX-5 represents a new class of benzodiazole antibiotics specifically designed to treat infections caused by Mycobacterium, particularly non-tuberculous Mycobacterium (NTM). This group encompasses a wide range of Mycobacterium species, excluding Mycobacterium tuberculosis and Mycobacterium leprae. Currently, over 190 NTM strains and 14 subspecies have been identified, with infection rates on the rise.
Addressing Challenges in NTM Treatment
The treatment of NTM infections poses significant challenges due to the lengthy duration of drug therapy, which is often accompanied by adverse reactions and limited efficacy. Patients with drug-resistant strains face particularly tough obstacles in achieving successful treatment outcomes. MicuRx’s MRX-5 aims to address these pressing issues in the management of NTM infections.-Fineline Info & Tech
